Last reviewed · How we verify
NCT07046585: FIND-CRC
Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
trial in Colo-rectal Cancer in 25,000 participants. Currently enrolling.
10 July 2027
Quick facts
| Lead sponsor | Natera, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 25,000 |
| Start date | 30 May 2025 |
| Primary completion | 10 July 2027 |
| Estimated completion | 30 September 2033 |
| Sites | 1 location across United States |
Conditions studied
- Colo-rectal Cancer — all drugs for Colo-rectal Cancer →
Sponsor
Natera, Inc.
Who can join
40 and older, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The FIND-CRC study is a prospective collection of samples and data from participants who are at average risk of developing colorectal cancer (CRC). Collected samples and data will be analyzed to evaluate the clinical performance of the Natera CRC Screening Test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07046585
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colo-rectal Cancer
Currently open trials in the same condition.
- NCT06645015 — The AIDPRO-CRC Trial · NA · recruiting
- NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC · Phase 2 · recruiting
- NCT06880055 — Shield Post-Approval Study Protocol · recruiting
- NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy · NA · recruiting
Other Natera, Inc. trials
Trials by the same sponsor.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT06620627 — Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection · recruiting
- NCT05309382 — Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation · completed
- NCT05312814 — Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management. · completed
- NCT05205551 — Prospera Test Evaluation in Cardiac Transplant (ProTECT) · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07046585 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Natera, Inc.
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07046585.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing